The Dor procedure is a medical technique used as part of heart surgery and originally introduced by the French cardiac surgeon Vincent Dor (b.1932).[1] It is also known as endoventricular circular patch plasty (EVCPP).
In 1985, Dor introduced EVCPP as a viable method for restoring a dilated left ventricle (LV) to its normal, elliptical geometry. The Dor procedure uses a circular suture and a Dacron patch to correct LV aneurysms and exclude scarred parts of the septum and ventricular wall and would prove to be the best option amongst the other methods of ventricular remodeling, i.e. Cooleys linear suturing and Jatenes circular external suturing.[citation needed] EVCPP is a relatively easy procedure that covers all aspects of successful heart restorationrestores ventricular shape, increases ejection fraction, decreases the left ventricular end systolic volume index (LVESVI), and allows for complete coronary revascularization.
The myocardium consists of a single, vascular, continuous tissue that wraps around itself, spiraling up from the apex of the heart, to form a helix with elliptically shaped ventricles.[2] This spiral produces an oblique muscle fiber orientation, meaning that the fibers form a more ventricle x shape, so that when fibers shorten 15%, it produces a 60% ejection fraction. Because of its elliptical shape and defined apex, the ventricle is subjected to a relatively low level of lateral stress.
A dilated left ventricle is generally due to the effects of a myocardial infarction. An occlusion, or blockage, results in either akinetic (non-beating) or dyskinetic (irregular beating) tissue downstream from the occlusion. This tissue is virtually useless. However, the volume of blood that fills the ventricle prior to contraction, or end-diastolic volume, remains constant, so the tissue that still functions has to do more work to eject the blood, as the Frank-Starling Laws demand.
The tension on the functioning tissue increases as it compensates for the work of the necrotic tissue, so, as per Laplace's law, the radius of the ventricle increases and the thickness of the ventricular wall decreases. The apex of the heart becomes circular, hypertrophy ensues in the viable myocardial tissue, and the valve opening widens. As the ventricle dilates, the muscle fiber orientation, which is critical to a good ejection fraction, becomes transverse, or more horizontal. Subsequently, the ejection fraction decreases; a 15% shortening produces only a 30% ejection fraction. The lateral stress on the ventricle increases. Overall, the dilated left ventricle cannot produce a strong enough contraction. Nonviable myocardial muscle mass (NVMMM) implies a distinct, inexpensively reproduced signature (electrocardiography and echocardiography) of several contemporary myocardial performance determinants when compared to viable myocardial muscle mass (VMMM). Ratio between the two in heart failure on a time curve is a determinate of compensatory geometric remodeling of the myocardium. Fick/Frank/Starling describes gas diffusion, fluid and compliance relationships of the myocardium, primarily in systole. Geometric derangement induced by nonviable myocardium (see myocardial infarction)is exponentially impacted and proportional to the weight of the performance determinant measured. Viable/Nonviable myocardial mass fraction is substantially reduced by surgical interventions such as Dor and Batista.
Doctors take a cardiac MRI to determine extent and location of the damage. Occasionally this reveals that the patient may be better suited for biventricular pacing or a defibrillator, but if the cardiologist determines that the Dor procedure is necessary, then the patient must display other symptoms to indicate that they would be a good candidate, including: angina, heart failure, arrhythmias or a combination of the three, large areas of akinesis or dyskensis, ejection fraction of less than forty percent
Contraindications include: dysfunctional right ventricle, pulmonary hypertension, dysfunction at the base of the heart, systolic pulmonary artery pressure greater than 60mmHg (in the absence of severe mitral regurgitation)
Surgeons usually perform the Dor procedure following a coronary artery bypass graft (CABG). EVCPP consumes only approximately twenty minutes of the three- to four-hour procedure.
To begin a basic remodeling, the surgeon makes an incision at the center of the depressed area on the LV wall and removes blood clots and endocardial scar tissue. To restore the heart to its elliptical shape, an endoventricular suture is put in place and a longitudinal tuck is made to return the cardiac apex from the posterior to the front. The suture also serves as guidance for the patch location. The surgeon then inserts a balloon into the ventricular cavity to ensure correct size and sutures a Dacron patch, deflating the balloon and removing it before complete closure. The non-viable fibrous tissue is pulled over the patch, and surgical glue is occasionally used to complete the closure. When the lesion is placed on the anteroseptoapical wall of the heart, it will include the septum and apex more extensively than the lateral wall. As a result, the suture is placed deeply within the septum, and the new neck of the suture, which holds the Dacron patch, extends from the septum. Dor explicates this procedure in detail. When the lesion is placed on the posterolateral wall of the heart, a triangular patch is used and stabilized by the posterior mitral annulus. This placement of the lesion allows for mitral valve replacement to be easily conducted by the transventricular approach. (The surgeon does not have to incise the atrium, rather can replace the valve through the already incised ventricle.)
It is recommended that the patient be placed on a mild anti-coagulant post operation to reduce the risk of blood clots. Some surgeons suggest the use of stronger anti-coagulants.
The disadvantage to the Dor procedure is that it places synthetic tissue inside the LV cavity. However, it is possible to replace the Dacron patch with autologous tissue. The surgeon can make a semicircular patch, mobilized with a septal hinge, out of the endocardial scar or use autologous patches of the pericardium.
The Dor procedure requires a hospital stay of approximately 8 days, which is only one day longer than CABG, and the early mortality rate is about 5.6%. Post-operation, the patient does not have any lifestyle constraints other than those associated with CABG. There is a 4% chance the patient will require another cardiac operation: 18% of patients who underwent CABG had recurrent heart failure.[3] Because the Dor procedure restores the left ventricle to its correct, elliptical orientation, it results in a mean ejection fraction increase of 12.5%. This number continues to improve over the patients lifetime, and patients can expect to live an extra 410 years, which is 3.3% longer than CABG alone with virtually no extra risk.[3]
See the article here:
- Cardiac MR PET CT Program - Massachusetts General Hospital, Boston, MA - April 12th, 2018 [April 12th, 2018]
- The History, Physical Examination, and Cardiac ... - April 21st, 2018 [April 21st, 2018]
- Cardiac Remodeling and Its Significance - Verywell - May 13th, 2018 [May 13th, 2018]
- AndrewMcCulloch - Cardiac Mechanics Research Group - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardiac Nursing Events ... - June 3rd, 2018 [June 3rd, 2018]
- Cardiac MR PET CT Program - Massachusetts General Hospital ... - June 5th, 2018 [June 5th, 2018]
- Cardiac resynchronization therapy - Wikipedia - June 23rd, 2018 [June 23rd, 2018]
- Cardiac Remodeling and Its Significance - verywellhealth.com - October 5th, 2018 [October 5th, 2018]
- Ventricular remodeling - Wikipedia - December 21st, 2018 [December 21st, 2018]
- The Significance of Cardiac Remodeling - verywellhealth.com - December 21st, 2018 [December 21st, 2018]
- Ventricular hypertrophy - Wikipedia - December 26th, 2018 [December 26th, 2018]
- Cardiac remodelingconcepts and clinical implications: a ... - April 3rd, 2019 [April 3rd, 2019]
- Emerging roles of proteoglycans in cardiac remodeling ... - May 23rd, 2019 [May 23rd, 2019]
- Antibody could fine-tune recovery from heart attack - Futurity: Research News - September 27th, 2019 [September 27th, 2019]
- What are the respiratory effects of e-cigarettes? - The BMJ - October 3rd, 2019 [October 3rd, 2019]
- AI Pinpoints Genes Associated With Heart Failure - Forbes - October 3rd, 2019 [October 3rd, 2019]
- PH Common in Myeloproliferative Neoplasms, Linked to Diastolic Dysfunction - The Cardiology Advisor - October 26th, 2019 [October 26th, 2019]
- Effects of genetic transfection on calcium cycling pathways mediated by double-stranded adeno-associated virus in postinfarction remodeling - DocWire... - November 6th, 2019 [November 6th, 2019]
- Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019 - GlobeNewswire - November 15th, 2019 [November 15th, 2019]
- Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights - P&T Community - November 15th, 2019 [November 15th, 2019]
- Ibrutinib and Hypertension in CLL: What Are the Risks? - Cancer Therapy Advisor - November 23rd, 2019 [November 23rd, 2019]
- What's being done to close the research gap when it comes to men's and women's cardiac health - The Loop - November 23rd, 2019 [November 23rd, 2019]
- Heart Ventricle Remodeling - an overview | ScienceDirect ... - November 26th, 2019 [November 26th, 2019]
- Denise Merkl, 1949-2019 The Times-Independent - The Times-Independent - December 16th, 2019 [December 16th, 2019]
- Is There a Future for CAR T-Cell Therapy in Heart Failure? - AJMC.com Managed Markets Network - December 16th, 2019 [December 16th, 2019]
- $13 Million Grant to Probe the Genome of Heart Cells - PRNewswire - December 18th, 2019 [December 18th, 2019]
- TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure - BioSpace - December 18th, 2019 [December 18th, 2019]
- News - Michigan Lawmaker to Offer CON Reforms - The Heartland Institute - December 28th, 2019 [December 28th, 2019]
- Personalized Medicine for AFib: How Electric Activity in the Heart Can Predict Individual Progression of Atrial Fibrillation - DocWire News - December 28th, 2019 [December 28th, 2019]
- Cardiac Restoration Systems Market Drives, Emerging Trends, Key Value And Forecast 2025 - Industry Mirror - December 31st, 2019 [December 31st, 2019]
- New Living Machines Are Created in the Lab - Tufts Now - January 16th, 2020 [January 16th, 2020]
- Man thinks sepsis was a cold and loses his leg on his 40th birthday - Information-Analytic Agency NEWS.am - January 25th, 2020 [January 25th, 2020]
- Could Colchicine Be the New Aspirin? - Medscape - January 28th, 2020 [January 28th, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - Renal and Urology News - January 28th, 2020 [January 28th, 2020]
- Link between chronic kidney disease and heart failure is identified in patients - UAB News - February 9th, 2020 [February 9th, 2020]
- Advancing an oral drug for pulmonary arterial hypertension - Penn: Office of University Communications - February 15th, 2020 [February 15th, 2020]
- MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR - TCTMD - February 15th, 2020 [February 15th, 2020]
- Varied Nightly Bedtime, Sleep Duration Linked to CVD Risk - Medscape - March 4th, 2020 [March 4th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Business Wire - March 4th, 2020 [March 4th, 2020]
- Slump in Production of Absorbable Heart Stent Amidst Covid-19 Outbreak to Diminish Prospects of Sales - Jewish Life News - May 7th, 2020 [May 7th, 2020]
- Cardiol Therapeutics files patent to use CBD therapies for patients with coronavirus - Proactive Investors USA & Canada - May 7th, 2020 [May 7th, 2020]
- The Effector Cells and Cellular Mediators of Immune System Involved in Cardiac Inflammation and Fibrosis after Myocardial Infarction - DocWire News - May 7th, 2020 [May 7th, 2020]
- Cardiac Restoration Systems Market Detailed Analysis and Forecast 2018-2028 3w Market News Reports - 3rd Watch News - May 16th, 2020 [May 16th, 2020]
- LV Mass Regression After TAVR Linked to Better Long-term Outcomes - TCTMD - May 16th, 2020 [May 16th, 2020]
- Hypoxic Training Equipment Industry to 2026; Featuring Profiles of Biomedtech Australia, Go2 Altitude, Gooxygen, Higher Peak, and More - GlobeNewswire - May 16th, 2020 [May 16th, 2020]
- Surplus antioxidants are pathogenic for hearts and skeletal muscle - The Mix - May 16th, 2020 [May 16th, 2020]
- $125619 awarded in spring Community Needs Grants - The MidWeek - May 20th, 2020 [May 20th, 2020]
- Absorbable Cardiac Stent Market 2020-2026 Growth Trends, Leading Players, Competitive Strategies and 2026 Future Prospect - Cole of Duty - June 15th, 2020 [June 15th, 2020]
- The Protective Effects of Liguzinediol on Congestive Heart Failure Induced by Myocardial Infarction and Its Relative Mechanism - DocWire News - June 19th, 2020 [June 19th, 2020]
- ABSORBABLE HEART STENT Sales Market 2020-2026: Analysis by Growth Factors, Key Trends and Competitive Strategies - Cole of Duty - June 19th, 2020 [June 19th, 2020]
- Absorbable Heart Stent Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:... - June 19th, 2020 [June 19th, 2020]
- Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease - Science Advances - June 19th, 2020 [June 19th, 2020]
- Worldwide Comprehensive Review of Absorbable Cardiac Stent Market Trends and Its Development - 3rd Watch News - June 22nd, 2020 [June 22nd, 2020]
- Absorbable Heart Stent Market In-deep Analysis And Experts Review Report 2020-2026 - Cole of Duty - June 22nd, 2020 [June 22nd, 2020]
- Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No... - July 1st, 2020 [July 1st, 2020]
- Cardiac Restoration Systems Market Analysis with Key Players, Applications, Trends and Forecast to 2027 - Jewish Life News - July 1st, 2020 [July 1st, 2020]
- Women Thrive on Baroreflex Activation for Heart Failure - Medscape - July 1st, 2020 [July 1st, 2020]
- Meet Inspiring young Doctor from Gallipolis, Ohio USA: Dr Wilton Triggs II - International Business Times, Singapore Edition - August 19th, 2020 [August 19th, 2020]
- Absorbable Heart Stent Market Research 2020-Competitive Insights: Abbott Laboratories, Biotronik, Arterial Remodeling Technologies, Amaranth Medica -... - August 19th, 2020 [August 19th, 2020]
- Novel mechanism connects SPEG, RyR2 and atrial fibrillation - Baylor College of Medicine News - August 19th, 2020 [August 19th, 2020]
- Comprehensive Analysis On Absorbable Heart Stent Market Insights Abbott Laboratories, Biotronik, Arterial Remodeling Technologies, Amaranth Medica -... - August 28th, 2020 [August 28th, 2020]
- Lincolnton man wrestles with COVID and wins | News - Lincoln Times-News - August 28th, 2020 [August 28th, 2020]
- Impact of sex on timing and clinical outcome of septal myectomy for obstructive hypertrophic cardiomyopathy - DocWire News - August 28th, 2020 [August 28th, 2020]
- Adverse Remodeling in Atrial Fibrillation Following Isolated Aortic Valve Replacement Surgery - DocWire News - August 28th, 2020 [August 28th, 2020]
- EphrinA1-Fc Attenuates Ventricular Remodeling and Dysfunction in Chronically Nonreperfused WT but not EphA2-R-M mice - DocWire News - August 28th, 2020 [August 28th, 2020]
- Business Notebook: Several 'pro-business' laws now in effect; SEMO joins forces with Codefi - Southeast Missourian - August 31st, 2020 [August 31st, 2020]
- Global Absorbable Heart Stent Market Covid-19 Impact Analysis, Leading Player, Application, New Product Developments and 2024 Forecast - The Daily... - August 31st, 2020 [August 31st, 2020]
- Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week - DocWire News - August 31st, 2020 [August 31st, 2020]
- Microengineered 3D pulmonary interstitial mimetics highlight a critical role for matrix degradation in myofibroblast differentiation - Science... - September 15th, 2020 [September 15th, 2020]
- 3D curvature-instructed endothelial flow response and tissue vascularization - Science Advances - September 19th, 2020 [September 19th, 2020]
- FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity - Science Advances - September 19th, 2020 [September 19th, 2020]
- Denervation Therapy Ventures Where Drugs Have Failed: HFpEF - Medscape - October 14th, 2020 [October 14th, 2020]
- Comprehensive Report on Absorbable Heart Stent Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Impact Of Covid 19 Analysis... - November 26th, 2020 [November 26th, 2020]
- Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study... - November 26th, 2020 [November 26th, 2020]
- NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 -... - December 17th, 2020 [December 17th, 2020]
- Elite Soccer Players Have Big Hearts and That's Okay - Medscape - December 20th, 2020 [December 20th, 2020]
- A high triglyceride-glucose index is associated with left ventricular dysfunction and atherosclerosis - DocWire News - January 20th, 2021 [January 20th, 2021]
- Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System - Business Wire - January 20th, 2021 [January 20th, 2021]
- Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis - DocWire... - January 20th, 2021 [January 20th, 2021]
- Global Absorbable Heart Stent Market Development Factors 2020 Overview by Regional Analysis, Industry Size, Business Share, Growth Rate Forecast to... - January 31st, 2021 [January 31st, 2021]